Stifel Upgrades Editas Medicine to Buy, Raises Price Target to $17
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Dae Gon Ha has upgraded Editas Medicine (NASDAQ:EDIT) from Hold to Buy and raised the price target from $9 to $17.
September 29, 2023 | 8:45 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Editas Medicine has been upgraded from Hold to Buy by Stifel, with a price target increase from $9 to $17.
The upgrade from Hold to Buy and the increase in price target by Stifel analyst Dae Gon Ha indicates a positive outlook for Editas Medicine. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100